G1 Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell GTHX and other ETFs, options, and stocks.About GTHX
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib.
CEOJack Bailey
CEOJack Bailey
Employees100
Employees100
HeadquartersResearch Triangle Park, North Carolina
HeadquartersResearch Triangle Park, North Carolina
Founded2008
Founded2008
Employees100
Employees100
GTHX Key Statistics
Market cap216.02M
Market cap216.02M
Price-Earnings ratio-4.33
Price-Earnings ratio-4.33
Dividend yield—
Dividend yield—
Average volume581.95K
Average volume581.95K
High today$4.24
High today$4.24
Low today$3.52
Low today$3.52
Open price$3.52
Open price$3.52
Volume1.01M
Volume1.01M
52 Week high$5.00
52 Week high$5.00
52 Week low$1.08
52 Week low$1.08
GTHX News
Simply Wall St 20h
G1 Therapeutics (NASDAQ:GTHX shareholders incur further losses as stock declines 10% this week, taking five-year losses to 82% - Simply Wall StSome stocks are best avoided. We don't wish catastrophic capital loss on anyone. Spare a thought for those who held G1 Therapeutics, Inc. ( ) for five whole yea...
Yahoo Finance 21h
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights - Yahoo FinanceG1 Therapeutics - Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Gu...
Yahoo Finance 21h
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib - Yahoo FinanceG1 Therapeutics - Pepper Bio will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib in the US, Eu...
Analyst ratings
83%
of 6 ratingsBuy
83.3%
Hold
0%
Sell
16.7%